Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 7/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.48 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539497 | 1.00 | CAPN1 (0.51) | CAPN1CTSBDPP4DPP7PREP | |
| SCHEMBL13964352 | 1.00 | CAPN1 (0.51) | CAPN1CTSBDPP4DPP7PREP | |
| SCHEMBL24171144 | 1.00 | CAPN1 (0.51) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL20814039 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL20678315 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL21549060 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL23859841 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL23859842 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL22213513 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP | |
| Rapastinel SCHEMBL25266713 | 0.92 | CAPN1 (0.59) | CAPN1CTSBDPP4DPP7PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170049844-A1 | STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES | NAUREX INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-8951968-B2 | Methods of treating depression and other related diseases | NORTHWESTERN UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049844-A1 | STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDES | OPRL1, GAP43, VGF | CAPN1 3641/4885CTSB 1985/4885DPP4 1017/4885 |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | GRIN1, GRIN2A, GRIN3A | CAPN1 766/4885CTSB 3156/4885DPP4 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.